Twenty-two patients with advanced transitional cell bladder cancer were treated in a phase II trial exploring the possible synergy of cisplatin and interferon alpha 2b. Of the 20 evaluable patients, 7 (35%) had a partial response to the treatment, and only 6 patients were able to complete the full planned six cycles of treatment. Response rates, duration of responses, and overall survival of our patients are not superior to those expected by cisplatin alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000421-199706000-00024 | DOI Listing |
Publication Analysis
Top Keywords
phase trial
8
cisplatin interferon
8
interferon alpha
8
patients advanced
8
bladder cancer
8
patients
5
trial cisplatin
4
alpha patients
4
advanced bladder
4
cancer twenty-two
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!